Shilpen Patel

Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial

Elizabeth A. Mittendorf, Hong Zhang, Carlos H. Barrios et al. · The Lancet · 2020 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +16

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

David Miles, Joseph Gligorov, Fabrice André et al. · Annals of Oncology · 2021 · 729 citations · Full text

Medicine, Oncology, Pharmacology +17

First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis

Leisha A. Emens, Sylvia Adams, Carlos H. Barrios et al. · Annals of Oncology · 2021 · 468 citations · Full text

Medicine, Oncology, Pharmacology +17

Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer

Sylvia Adams, Véronique Dièras, Carlos H. Barrios et al. · Annals of Oncology · 2020 · 93 citations · Full text

Medicine, Oncology, Pharmacology +16

The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics.

Steven M. Kornblau, Peter F. Thall, Zeev Estrov et al. · PubMed · 1999 · 86 citations

Medicine, Hematology, Oncology +15